<img src="https://ml.globenewswire.com/Resource/Download/7d124852-a695-4916-a0bf-6ff3051c9a0c?size=2" nborder="0" align="left" hspace="5" vspace="5" title="BraveheartBio_Logo_Full Color.jpg" alt="Braveheart Bio, Inc."/>SAN FRANCISCO, Sept. 01, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY. Management will participate in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT. Interested parties may access a live webcast by visiting the News &amp; Events section of the Braveheart website at <a href="https://www.globenewswire.com/Tracker?data=HaC7aldKTarLiyKlsMk90s3xPkF0azqMSTz4IFWt6IPPgU53-OEyAHnh2CPRfdxv7Gb9JtsG8hgOHu6CZkACiqPG3eSZvw8bOvasmIiEYXI=" rel="nofollow" target="_blank" title="">https://ir.braveheart.bio/</a>, with replays available in a temporary archive following the event. About Braveheart Bio Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. Investor Relations Contact Alexander Sharif New Street Investor Relations <a href="https://www.globenewswire.com/Tracker?data=2fx8RcbmgGquZ1lJBo68p7eoO2HSYi26mqa01kc5XTtTukhtFlKMS61eZvcvn82HZSGfh95H7IlBhiwmkjKQ3svbgPPIjtDsCyb9tz9sEIMyv0c3iZEx0DRODan4XvYH" rel="nofollow" target="_blank" title="Alexander@NewStreetIR.com">Alexander@NewStreetIR.com</a> Media Contact FGS Global <a href="https://www.globenewswire.com/Tracker?data=ljaJE_DCI8qH4HD3awKWXTCFrxciGkRHauMXoau55xixvJvnXme5whfZApjO4x9NfyxHG8XeC3dxPnU0zTM7eioAdoPAJTW519j7ZxX9YIrklZNzwR_bGiNoHv2gEf6K" rel="nofollow" target="_blank" title="Braveheart-bio@fgsglobal.com">Braveheart-bio@fgsglobal.com</a>   <img alt="" src='https://ml.globenewswire.com/media/ZjcxMTlmZDctOThhOS00NGVlLWJmNTctYzkzODQ1YTFhMGIzLTEzMjQxNDAtMjAyNi0wOS0wMS1lbg==/tiny/Braveheart-Bio-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

Braveheart Bio to Participate in Cantor Global Healthcare Conference

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn